Summit Therapeutics to Present Breakthrough Research Updates at the 31st Annual ECCMID Conference, including a Top-Rated ePos...
July 01 2021 - 7:00AM
Summit Therapeutics Inc. (NASDAQ: SMMT) (the “Company”) today
announced that members of our scientific team will present
breakthrough research updates at the 31st European Congress of
Clinical Microbiology & Infectious Diseases (ECCMID), which
will be held virtually July 9 – 12. Our three posters to be
presented are as follows, one of which was designated as a Top
Rated ePoster by the ECCMID conference:
- ECCMID Top Rated ePoster:
Metagenomic Analysis of the Impact of the Precision Antibiotic
Ridinilazole, Compared to Vancomycin, on the Gut Resistome in a
Phase II Study
- Metagenomic Analysis of the
Differential Impact of Ridinilazole and Vancomycin on the Gut
Microbiota in a Phase II Study
- Identification of the Mechanism of
Action for Ridinilazole, a Phase III Antibiotic for Treatment of
Clostridioides difficile
Ridinilazole is our investigational drug
currently in Phase III Ri-CoDIFy clinical trials with the goal of
use as first-line therapy to treat initial infection and reduce
recurrence of Clostridioides difficile infection.
Clostridioides difficile, or C. difficile,
infection (CDI) is highly infectious disease that affects over
500,000 patients in the United States each year with approximately
25% of initial cases resulting in recurrent infections.
Along with emotional and physical suffering, symptoms
include inflammation of the colon, severe watery diarrhea, painful
abdominal cramping, nausea, fever, dehydration, and in more severe
cases, bowel perforation and sepsis. CDI is responsible for
an estimated 20,000 to 30,000 deaths in the US each year with
annual acute care costs estimated to be $5.4 billion.
Dysbiosis (dysfunction) of the gut microbiota is a major risk
factor for initial instances of and recurrence of the disease.
Upon the completion of the conference, each
poster will be available within the “Scientific Literature &
Publications” section of our website:
https://www.summittxinc.com/publications/.
About Summit Therapeutics
The overriding objective of Summit Therapeutics
is to create value for patients, hospital caregivers, and
community-based healthcare providers, as well as healthcare payers
around the world. We seek to create value by developing drugs
with high therapeutic efficacy - curing the cause of the patient's
condition with minimal or zero disease recurrence or antimicrobial
resistance, for the longest extent possible - and minimizing the
trauma caused to the patient and healthcare ecosystem by minimizing
serious side effects, disease recurrence, and inaccessibility to
our treatments as a result of financial or other barriers.
Summit Therapeutics, empowered by its Discuva Platform, the
Company’s innovative antibiotic discovery engine, supported by
BARDA and CARB-X funding, intends to be the leader in
patient-friendly and paradigm-shifting treatments for infectious
diseases and other significant unmet medical needs while being an
ally to physicians. Our new mechanism pipeline product
candidates are designed with the goal to become the
patient-friendly, new-era standard of care, by working in harmony
with the human microbiome to treat prospective patients suffering
from infectious disease, initially focusing on Clostridioides
difficile infections (CDI). Currently, Summit’s lead product
candidate, ridinilazole, is engaged in two pivotal global Phase III
trials, Ri-CoDIFy 1 & 2, each enrolling approximately 680
patients vs. the standard of care (vancomycin) for the treatment
and reduction of recurrence of C. difficile infections, in addition
to an adolescent trial, Ri-CoDIFy 3. Commercialization of
ridinilazole for the treatment and the reduction of recurrence of
CDI is subject to regulatory approvals. SMT-738, the second
candidate within Summit’s portfolio, is currently in the
IND-enabling phase for the treatment of multidrug resistant
infections, specifically those caused by carbapenem-resistant
Enterobacteriaceae (CRE).
For more information, please visit
https://www.summittxinc.com and follow us on Twitter @summitplc.
For more information on the Company’s Discuva Platform,
please visit
https://www.summittxinc.com/our-science/discuva-platform.
About C. difficile InfectionC. difficile
infection is a bacterial infection of the colon that produces
toxins causing inflammation of the colon and severe watery
diarrhea, painful abdominal cramping, nausea, fever, and
dehydration. CDI is highly contagious and can also result in more
serious disease complications, including bowel perforation, sepsis,
and death. CDI is a contagious infectious disease that
represents a serious healthcare issue in hospitals, long-term care
homes, and the wider community. Summit estimates that there
are approximately 500,000 cases of CDI each year across the United
States based on a meta-analysis published in the Journal of Global
Health, June 2019.
Contact Summit Investor Relations
Dave GancarzHead of Investor Relations &
Corporate Strategydavid.gancarz@summitplc.com
General Inquiries:
investors@summitplc.com
Summit Forward-looking Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the clinical and preclinical
development of the Company’s product candidates, the therapeutic
potential of the Company’s product candidates, the potential
commercialization of the Company’s product candidates, the timing
of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing
approvals, the impact of the COVID-19 pandemic on the Company’s
operations and clinical trials and other statements containing the
words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "would," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties inherent in the initiation of future clinical trials,
availability and timing of data from ongoing and future clinical
trials and the results of such trials, global public health crises,
including the coronavirus COVID-19 outbreak, that may affect timing
and status of our clinical trials and operations, whether
preliminary results from a clinical trial will be predictive of the
final results of that trial or whether results of early clinical
trials or preclinical studies will be indicative of the results of
later clinical trials, expectations for regulatory approvals, laws
and regulations affecting government contracts and funding awards,
availability of funding sufficient for the Company’s foreseeable
and unforeseeable operating expenses and capital expenditure
requirements and other factors discussed in the "Risk Factors"
section of filings that the Company makes with the Securities and
Exchange Commission. Accordingly, readers should not place undue
reliance on forward-looking statements or information. In addition,
any forward-looking statements included in this press release
represent the Company’s views only as of the date of this release
and should not be relied upon as representing the Company’s views
as of any subsequent date. The Company specifically disclaims any
obligation to update any forward-looking statements included in
this press release.
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Jul 2023 to Jul 2024